Maxygen Shares Rise on Possible Deal
From Bloomberg News
Roche Holding said it may pay Maxygen Inc. more than $230 million as part of a research agreement for hepatitis medicines.
The deal gives Roche worldwide marketing rights to potential treatments for hepatitis B and C, the Swiss company said.
Redwood City, Calif.-based Maxygen will get research and development funding for the first two years, as well as royalties and payments when development goals are met.
Shares of Maxygen jumped $1.55 to $9.66 on Nasdaq.
